Control of postoperative pain with morphine alone can require repeat dosing and in some cases be inadequate. Large morphine doses may increase side-effects such as nausea, vomiting, respiratory depression and sedation. The need for large doses of morphine may exist due to acute or chronic tolerance of opioids, or may merely be a requirement of some individual patients, possibly due to 'wind-up' 1 . Ketamine, an N-methyl-D-aspartate (NMDA) noncompetitive receptor antagonist, is an anaesthetic agent and at sub-anaesthetic doses (0.2-0.5 mg/kg) 2 , a potent analgesic. The NMDA receptor is a member of the glutamate receptor family and is an ion channel with excitatory properties 3 . Ketamine works by noncompetitive antagonism of the central calcium pore, as well as by inhibiting NMDA receptor activity through binding to the phencyclidine receptor site 3 . It would therefore be expected to have a more marked analgesic effect on high intensity nociceptive stimuli 4 than on low level pain as may be seen in opioidresistant postoperative pain, as well as neuropathic and cancer pain 5 . In previous studies comparing morphine alone with morphine and ketamine administered either as patient controlled analgesia or intramuscular injection [6] [7] [8] to patients with postoperative pain, there have been varying reports of effects. Javery et al 8 as well as Weinbroum 9 demonstrated pain scores that were lower in patients who received ketamine, but Reeves et al 10 in a later but similar study demonstrated alone.
In clinical practice, the authors have observed that in the early postoperative period where there is pain resistant to morphine, a bolus dose of ketamine may often lead to a marked reduction in pain and this effect has also been noted in opioid-resistant cancer pain. The reason may be related to the concept of preventive analgesia whereby the administration of a drug at any time during the peri-operative period provides a reduction in wind-up and thereby a reduction in pain scores or analgesic consumption, or both 1, 11 . This effect is seen to extend beyond the half-lives (t ½ ketamine=11-17 min) that would be the expected clinical duration of the drug. This concept may also have relevance in the prevention of central sensitisation and the development of chronic post surgical pain 12, 13 , as well as allowing earlier discharge from the recovery room through the improved management of postoperative pain.
SUMMARY
This double-blind randomised controlled trial was designed to determine if a single bolus dose of ketamine 0.25 mg/kg administered in the recovery room to patients with pain resistant to two doses of a standard morphine pain protocol, appreciably improves analgesia at rest and four hours postoperatively, compared to controls who receive morphine alone.
METHODS
Based on the data from a previous study at our institution 10 , we calculated that we needed 14 patients per group in order to have an 80% power to demonstrate a 25% reduction in pain scores in the ketamine group. We accepted a type I error of 0.05. We planned to recruit and study 40 patients to allow for drop-outs and non-normal data.
After attaining local hospital ethics committee approval, 41 patients of ASA I to III status were recruited to this randomised double-blinded trial. Patients were eligible for inclusion if they required more than two doses of morphine in the 11 point verbal rating scale (VRS) 14 , a sedation score less than or equal to one and a respiratory rate greater than eight. Exclusion criteria were known allergy to morphine, history of major psychiatric disturbance or currently taking psychiatric medications, chronic morphine usage, chronic pain syndrome, unable to gain reliable pain score in recovery due to language barriers or residual anaesthesia, known pregnancy, where the primary anaesthetist preferred an alternative therapy, age <8 years, weight <50 kg or >100 kg, intraoperative use of ketamine, or use of major regional block.
Randomisation was by a table of random numbers. Patients were randomly allocated to receive either ketamine 0.25 mg/kg or the control infusion of normal saline. The study drug was given as a constant IV infusion over 10 minutes, thus aiming to minimise unblinding by bolus administration. Both solutions were prepared in the hospital pharmacy and were identical in appearance. The pharmacist who prepared the solutions was not involved in any other part of the study. Both the nurse administering the infusion and collecting the data and the patient were blinded to the identity of the solution.
Intravenous morphine continued to be administered as needed during the infusion according to our protocol for the recovery room. This protocol applies dose of morphine 4 mg and then 2 mg increments as failure, ischaemic heart disease, morbid obesity, renal for the purposes of the morphine protocol. They receive morphine 2 mg as an initial bolus for postoperative pain followed by 1 mg increments. No other analgesics were to be given in the recovery room. The anaesthetic technique for each study patient was at the discretion of the treating anaesthetist in order to make our results broadly applicable to many clinical circumstances. Data were collected from patients in the recovery room and at four hours post discharge from the recovery room on the ward. Data collection began at the time of commencement of the study infusion and at discharge from recovery and at four hours post discharge from recovery. Study data included sedation scores (0=alert, 1=awake but drowsy, 2=drowsy but rousable to voice or touch, 3=unrousable), VRS scores, heart rate (HR), blood pressure (SBP) and respiratory rate. At 24 hours, total morphine (or equivalent opioid) consumption was reviewed. The primary end-points were pain scores at discharge and four hours postoperatively. Secondary endpoints have been described in Table 1 and were also collected in the recovery room and at fours hours post discharge. Informed patient consent to use the data collected was obtained retrospectively from patients once they had from the effects of anaesthesia.
Outcome measures were compared using linear models adjusting for age, gender, duration and type of surgery and other analgesics. The number of complications was compared using chi-squared 
RESULTS
Of the 41 patients recruited to the trial, 19 (46%) received ketamine and 22 (54%) received saline (control). Patient demographics were similar between groups and are listed in Table 2 All patients had severe uncontrolled pain at baseline and VRS scores between groups were similar. They were 7.63 (mean, SD 1.42) in the ketamine plus morphine group (K) and 8.09 (mean, SD 1.54) in the control group (M). Over the 45 minutes that data was collected in the recovery room, there was a reduction in pain scores in both groups. Mean VRS score in the ketamine group was reduced to 5.16 (95% CI 4.14-6.18) versus control group 6.28 (95% CI 5.34-7.23) (P pain scores at discharge from recovery room, K=3.79 (SD 1.96) and M=4.23 (SD 2.18) (P=0.38), nor at four hours after discharge from recovery room K=3.47 (SD 2.39) and M=3.77 (SD 2.49) (P=0.3, Figure 1 ).
There was no difference observed between groups on any of our secondary endpoints (Table 3) . Although mean morphine consumption at both four hours and 24 hours was slightly less in ketamine group (14.4 mg No difference in sedation was noted between the two groups ( Figure 2) .
Requirements for anti-emetics and duration of stay in the recovery room were not affected by ketamine administration.
DISCUSSION
We were unable to demonstrate that a single dose of ketamine 0.25 mg/kg, given in the recovery room as a rescue analgesic to patients in severe pain despite standard morphine dosing had an appreciable effect (25% reduction) on postoperative pain scores compared to morphine alone. The absolute reduction in pain scores that we observed in the ketamine group was not as large as those reported in other studies 9 and yet were greater than those detected in two recently published metaanalyses 15, 16 . Whilst previous trials have used wide variations in ketamine doses (0.1-3.4 mg/kg) the observed analgesic response does not appear to be obviously dose-related. In fact, a number of trials have shown 0.25 mg/kg to be an effective dose 16 in the postoperative setting. The reasons for the different reductions in VRS scores in response to ketamine from various similar trials are not easy to explain.
There is a belief that the timing of ketamine administration in relation to surgery may be 17, 18 , particularly in relation to preventing activation of NMDA receptors and wind-up, but large meta-analyses have failed to analgesia and timing of administration 15 . One of the concerns with using ketamine as an analgesic agent is its potential for side-effects, in particular hallucinations and sedation. In our study, we observed no adverse events associated with the use of ketamine, which is consistent with other trials using a similar dose. However given that previous studies 15 have demonstrated this complication to be uncommon, our study was underpowered to detect this. The absence of hallucinations in our study may be in part explained by residual anaesthesia in the early postoperative period which may mitigate the potential hallucinatory effects of ketamine. Consistent with other studies 16 using a similar dose of ketamine, we observed no difference in sedation between groups.
Given the possible morphine-sparing effects of ketamine, there is potential to see a reduction in postoperative nausea and vomiting in the group receiving ketamine. We were unable to demonstrate nausea and vomiting although this study was not powered to detect such a difference. It is consistent with the studies by Elia et al 15 and Subramaniam et al 16 who also found no difference in postoperative nausea and vomiting rates. It does, however, contrast starkly with the study by Weinbroum 9 which found postoperative nausea and vomiting rates of 38% in the morphine group compared with 12% in the ketamine group.
Ketamine's properties as both an anaesthetic and analgesic agent have long been appreciated and with the increasing knowledge and understanding of the many mechanisms contributing to pain there has been renewed interest in the role of ketamine NMDA receptor are now well understood and the more clearly described. Despite some recent similar trials 9 to treat severe pain, we were unable to reproduce these results. We did not demonstrate an effective role for ketamine in the management of problematic postoperative pain.
